Open AccessThe Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review
Author(s) -
Kamil Kaplanov
Publication year - 2021
Publication title -
sovremennaâ onkologiâ
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/18151434.2021.2.200936
Subject(s) - mantle cell lymphoma , tyrosine kinase inhibitor , refractory (planetary science) , tyrosine kinase , bruton's tyrosine kinase , lymphoma , cancer research , ibrutinib , medicine , oncology , biology , leukemia , cancer , receptor , astrobiology , chronic lymphocytic leukemia
The meeting of the expert council concerning the application of new highly selective inhibitor of Brutons tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma was held in Moscow on April 21, 2021. The leading Russian experts in the field of oncohematology took part in the meeting.